Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.

Check Now!
SALE Diffuse Large B-cell Lymphoma Market Report
Diffuse Large B-cell Lymphoma Market Report
Diffuse Large B-cell Lymphoma - Market Insight, Epidemiology And Market Forecast - 2032
  • Published Date : Sep 2023

  • Pages : 200

  • Delivery Time : 24 Hours

  • Region : United States, EU5, Japan

Diffuse Large B-cell Lymphoma Market

DelveInsight's “Diffuse Large B-cell Lymphoma - Market Insights, Epidemiology and Market Forecast– 2032” report delivers an in-depth understanding of the DLBCL, historical and forecasted epidemiology as well as the DLBCL market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

DLBCL market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM DLBCL market size from 2019 to 2032. The report also covers current DLBCL treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Report Metrics

Details

Study Period

2019 to 2032

Forecast Period

2023 to 2032

Geographies Covered

The US, EU4 (Germany, France, Italy, and Spain) and UK, and Japan

DLBCL Market Assessment

  • Total Market Size
  • Market Size by Therapies
  • Market Size by Class

Market CAGR

Request Sample PDF to Know

Diffuse Large B-cell Lymphoma Market Size

Request Sample PDF to Know

Diffuse Large B-cell Lymphoma Companies

AbbVie and Genmab, Merck, Roche, Xencor and Janssen, Denovo Biopharma, Calithera Biosciences, IMV, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, Debiopharm, Seagen, Takeda, AstraZeneca, Gilead Sciences, and others.

Diffuse Large B-cell Lymphoma Treatment Market

Diffuse Large B-cell Lymphoma Overview

Diffuse Large B-cell Lymphoma (DLBCL) is an aggressive (fast-growing) and the most common type of non-Hodgkin’s lymphoma that can arise in lymph nodes or outside of the lymphatic system (such as in gastrointestinal tract, testes, thyroid, skin, breast, bone, or brain). Often, the first sign of DLBCL includes painless, rapid swelling in the neck, underarms, or groin that is caused by enlarged lymph nodes. For some patients, the swelling may be painful. Other symptoms may include night sweats, fever, and unexplained weight loss. Patients may notice fatigue, loss of appetite, shortness of breath, or pain. Generally, it has been observed that DLBCL affects patients of all age groups with a wide range of presentations concerning localization, morphology, and molecular mechanisms.

There are several subtypes of DLBCL. Classification of the DLBCL subtype requires examination of cell morphology (shape, structure, and form) as well as specialized tests including immunohistochemistry, flow cytometer, fluorescence in situ hybridization (FISH) and molecular testing.

WHO/REAL classification

1. DLBCL, not otherwise specified (NOS):

  • T-cell/histiocyte rich large B-cell lymphoma
  • Primary DLBCL of the central nervous system (CNS)
  • Primary cutaneous DLBCL, leg type
  • Epstein-Barr virus (EBV)-positive DLBCL of the elderly
  • Germinal center B-cell (GCB)-DLBCL
  • Activated B-cell (ABC)-DLBCL

2. DLBCL associated with chronic inflammation:

  • Primary mediastinal lymphoma
  • Intravascular large B-cell lymphoma
  • Anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma

Diffuse Large B-cell Lymphoma Diagnosis

A tissue biopsy is needed for a definitive diagnosis of DLBCL. Because DLBCL is a blood cancer, it is important to look for any signs of lymphoma across the entire body. This is usually done with a positron emission tomography (PET) scan. A morphological diagnosis of DLBCL should be confirmed in all cases by immunophenotypic investigations, either immunohistochemistry (IHC) or flow cytometry or a combination of both techniques.

Diffuse Large B-cell Lymphoma Treatment

DLBCL treatment is typically begun shortly after diagnosis with the intent of obtaining a durable remission or cure. A combination of chemotherapy and a monoclonal antibody targeting CD20 remains the backbone of most treatments. The most widely used combination chemotherapy regimen for DLBCL is R CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) that is usually given in 21-day cycles. Sometimes etoposide (VePesid, Toposar, Etopophos) is added to the R-CHOP regimen, resulting in a drug combination called R-EPOCH. Sometimes treatment may involve radiation therapy. For many patients with DLBCL, the initial treatment can lead to disease remission (disappearance of signs and symptoms). However, for patients in whom the disease becomes refractory (no longer responds to treatment) or relapses (returns after treatment), secondary therapies may be successful.

Diffuse Large B-cell Lymphoma Epidemiology

The Diffuse Large B-cell Lymphoma epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total incident population of DLBCL, gender-specific population of DLBCL, age-specific population of DLBCL, type-specific population of DLBCL, and stage-specific population of DLBCL in the 7MM market covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2019 to 2032.

Key Findings

This section provides glimpse of the DLBCL epidemiology in the 7MM

Country Wise- Diffuse Large B-cell Lymphoma Epidemiology

The epidemiology segment also provides the DLBCL epidemiology data and findings across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

  • The total incident population of DLBCL in the 7MM comprised of 73,598 cases in 2021 and are projected to increase during the forecast period.
  • The total incident population of DLBCL in the United States is 29,958 in 2021.
  • The United States contributed to the largest incident population of DLBCL, accounting for ~ 41% of the 7MM in 2021.
  • Among EU4 countries, Germany accounted for the highest number of DLBCL cases, whereas Spain accounted for the lowest cases in 2021.
  • In Japan, the total incident population of DLBCL was 11,409 in 2021 and is anticipated to rise during the forecast period.
  • Among the total 26,064 cases of DLBCL, NOS type in 2021 in the US, GCB subtype accounts for 11,983 cases while ABC subtype accounts for 17,975 cases.
  • In 2021, males and females accounted for 16,777 and 13,182 cases respectively in the United States.
  • In 2021, the total cases of DLBCL in Stage I, Stage II, Stage III, and Stage IV were identified to be 7,190, 5,992, 5,093, and 11,684

DLBCL Drug Chapters

Drug chapter segment of the DLBCL report encloses the detailed analysis of DLBCL marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the DLBCL clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed DLBCL Drugs

YESCARTA (axicabtagene ciloleucel): Kite Pharma (a subsidiary of Gilead Sciences)

YESCARTA is a CD19-directed genetically modified autologous T-cell immunotherapy. In April 2022, Kite announced that FDA has approved YESCARTA for adult patients with LBCL that is refractory to first-line chemo immunotherapy or that relapses within 12 months of first-line chemo immunotherapy. In October 2017, the FDA granted approval to YESCARTA for treating adult patients with R/R LBCL after two or more lines of systemic therapy. In October 2022, Gilead announced that European Commission has approved the use of YESCARTA to treat adult patients with DLBCL and HGBL who relapse within 12 months from completion of or are refractory to, first-line chemo immunotherapy. The company is planning to file the application for YESCARTA in 1L setting on the basis of ZUMA-23 in 2025 or beyond.

KYMRIAH (tisagenlecleucel): Novartis

KYMRIAH is a CD19-directed genetically modified autologous T-cell immunotherapy comprised of autologous T cells that are genetically modified using a lentiviral vector to encode an anti-CD19 chimeric antigen receptor. KYMRIAH is approved for treating adult patients with R/R LBCL after two or more lines of systemic therapy, including DLBCL not otherwise specified, primary mediastinal large B-cell, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

XPOVIO (selinexor): Karyopharm

XPOVIO, is a first-in-class, oral selective inhibitor of nuclear export (SINE) compound. It functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus. The FDA granted accelerated approval to XPOVIO for adult patients with R/R DLBCL, not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. In November 2018, Karyopharm’s selinexor received FTD from FDA to treat patients with R/R DLBCL.

POLIVY (polatuzumab vedotin-piiq): Roche/Chugai Pharmaceuticals

POLIVY (polatuzumab vedotin-piiq) is a CD79b-directed antibody-drug conjugate (ADC) consisting of three components: the humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b; the small molecule anti-mitotic agent MMAE; and a protease-cleavable linker maleimidocaproyl-valine-citrulline-p-amino benzyloxy carbonyl (mc-VC-PAB) that covalently attaches MMAE to the polatuzumab antibody. In June 2019, the US FDA granted accelerated approval to POLIVY (polatuzumab vedotin-piiq), in combination with the chemotherapy bendamustine and a rituximab product (known as “BR”), to treat adult patients with DLBCL that has progressed or returned after at least two prior therapies. In the May 2022, POLIVY combination received EU approval for previously untreated DLBCL.

Note: Detailed current therapies assessment will be provided in the full report of DLBCL

Emerging DLBCL Drugs

Epcoritamab: AbbVie and Genmab

Epcoritamab (also known as GEN3013) is an investigational IgG1-bispecific antibody created using Genmab’s proprietary DuoBody technology. Epcoritamab is being codeveloped by AbbVie and Genmab as part of the companies’ oncology collaboration. The companies will share commercial responsibilities in the US and Japan, with AbbVie responsible for further global commercialization. In October 2022, AbbVie announced that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA) for epcoritamab to treat adult patients with R/R DLBCL after two or more lines of systemic therapy. In November 2022, AbbVie announced that the US FDA has accepted for priority review the Biologics License Application for epcoritamab, to treat adult patients with relapsed/refractory LBCL after two or more lines of systemic therapy. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of May 21, 2023.

Glofitamab: Roche

Glofitamab (CD20-TCB, RG6026) is an investigational CD20xCD3 T-cell engaging bispecific antibody designed to target CD20 on the surface of B cells and CD3 on the surface of T cells. Roche filed for approval of glofitamab in April 2022 in the EU for 3L DLBCL. Findings from the expansion study, known as NP30179, have been submitted to the European Medicines Agency (EMA). An application to the FDA in the United States is planned for the end of 2022. According to the company, data readout from the Phase III glofitamab + GemOx (STARGLO) trial in 2L+ DLBCL is expected by 2023/2024. The company anticipates submission to health authorities for glofitamab + chemotherapy in 2L DLBCL by 2024 and glofitamab + chemotherapy in 1L circulating tumor (ct) DNA+ high-risk DLBCL by 2025 and beyond.

ALLO-501A: Allogene Therapeutics

ALLO-501A, a next-generation anti-CD19 Allo CAR-T, is engineered without the rituximab recognition domains included in ALLO-501, which could allow for use in a broader patient population, including NHL patients with recent rituximab exposure; AALLO-501A uses the Cellectis TALEN technology. In October 2022, the company initiated the Phase II clinical trial of ALLO-501A (the ALPHA2 trial) in patients with R/R LBCL. The company is also in the process of initiating the EXPAND trial, which is intended to demonstrate the contribution of ALLO-647 to the lymphodepletion regimen. Allogene is also conducting a long-term follow-up in the Phase I clinical trial (the ALPHA trial) of ALLO-501 in patients with R/R NHL. Assuming favorable outcomes and subject to FDA discussions, the company plans to seek FDA approval of ALLO-501A based on the ALPHA2 trial. According to the company, the readiness of the Phase II (ALPHA3) trial of ALLO-501A is expected by 2023. Target enrollment completion of the ALPHA2 trial is expected by 1H 2024

LUNSUMIO (mosunetuzumab): Roche and Biogen

LUNSUMIO (mosunetuzumab, RG7828) is a first-in-class CD20 x CD3 T-cell engaging bispecific antibody designed to target CD20 on the surface of B cells and CD3 on the surface of T cells. In July 2022, Roche announced that the US FDA has accepted the company’s Biologics License Application (BLA) and granted Priority Review for LUNSUMIO to treat adults with R/R FL who have received at least two prior systemic therapies. Currently, Roche is investigating the LUNSUMIO plus POLIVY in Phase III (SUNMO) trial in 2L DLBCL, with most trial locations outside the 7MM except for Japan. With an expected submission in the US by 2025 and beyond and by 2024 in Japan, as per Chugai Pharmaceutical.

Zamtocabtagene autoleucel (MB-CART2019.1): Miltenyi Biomedicine

Zamtocabtagene autoleucel (MB-CART2019.1) targets the combination of CD19 and CD20 proteins in B cells. This investigational therapy candidate has been selected for the PRIority MEdicines scheme (PRIME) in the European Union. Additionally, the company has submitted an Investigational New Drug (IND) application for a new CAR T-cell therapy to the FDA in the United States. Promising results from 2-year follow-up data from the Phase I/II trial of zamtocabtagene autoleucel, DALY 1 (NCT03870945) in elderly patients with R/R DLBCL at the EHA 2022, represent the rationale for the ongoing randomized Phase II trials, DALY 2-EU (NCT04844866) and DALY 2-US (NCT04792489). DALY 2-EU is currently enrolling and investigating the superiority of MB-CART2019.1 over conventional immunochemotherapy in older patients with R/R DLBCL who are not eligible for high-dose chemotherapy or autologous stem cell transplantation. DALY 2-US is currently enrolling and investigating MB-CART2019.1 in adults with R/R DLBCL after receiving at least two lines of therapy.

Note: Detailed emerging therapies assessment will be provided in the final report.

DLBCL Market Outlook

Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma for which a cure is usually the therapeutic goal of optimal treatment. There are several treatment options for DLBCL, which include chemotherapy, radiation, and immunotherapy. The aforementioned treatment modalities have been used, alone or in combination, in the last decades to treat DLBCL. Chemotherapy is the main way to treat DLBCL.

The DLBCL market growth over the forecast period is also being driven by an increase in pipeline candidates for the development of therapies for better recovery of DLBCL. Rituximab's approval altered the DLBCL therapeutic landscape. For DLBCL patients, chemo immunotherapy is the standard of care. In addition, numerous drugs that have recently been approved have transformed the treatment landscape for individuals with R/R DLBCL in 2L and 3L.

In recent years, the FDA has approved seven new therapies in the R/R DLBCL setting across a range of different modalities including CAR-T therapies, small molecules, monoclonal antibodies and antibody-drug conjugates.

The notable and exponential understanding of cellular processes that are deregulated during lymphomagenesis, such as signal transduction pathways, transcriptional and translational regulation, protein stability and degradation, cell cycle regulation, and mitosis and apoptosis, as well as the study of the microenvironment has led to the discovery and progress of new targeted therapies.

Many novels targeted agents under trial are being tested in double-hit lymphoma including the BCL2 inhibitor, PI3K inhibitor, and an mTOR inhibitor. The INKa/ARF deletion causes genomic instability. Constitutive activation of NFkB is being targeted in several trials of proteasome inhibitors, immunomodulatory agents, and B cell receptor signaling pathway inhibitors.

There is currently no therapy approved for patients who have failed CAR-T. Moreover, current NCCN treatment guidelines suggest a variety of treatment options for patients in second or later relapse who previously received CAR-T, including clinical trial participation, alternative second-line chemotherapy (but the guidelines note patients are unlikely to derive benefit from this approach), palliative radiation therapy, or best supportive care. There is no established standard of care for treating adults with DLBCL once a CAR-T treatment fails, thus highlighting the need for new, efficient therapeutic options.

Even though the reimbursement of CAR-T therapies represents a challenge for healthcare providers, insurers, and government agencies, have successfully reached the majority of the markets by considering the patient pool demand. While determining the cost and reimbursement, various factors such as pharmacoeconomic analysis and outcome-based responses, as well as the added value to society have been evaluated. The CAR T-cell-related toxicity such as the cytokine-release syndrome and neurotoxicity remain important potential complications of this therapy. To overcome these limitations second generations CAR T-cell therapies are emerging with more safety and efficacy. If these limitations have been overcome, these are going to be the potential drivers of the market.

The pipeline possesses multiple potential DLBCL drugs in late- and mid-stage developments to be launched shortly. Key players involved in robust research and development include enzastaurin, ADCETRIS, epcoritamab, LUNSUMIO, glofitamab, zilovertamab vedotin, maveropepimut-S, plamotamab, mivavotinib, zamtocabtagene autoleucel, ALLO-501A, and others in combination with other therapies or as a monotherapy are some of the major players that are going to alter the market dynamics in the coming years.

Key Findings

This section includes a glimpse of the DLBCL market in 7MM.

  • The total DLBCL market size in the 7MM was USD 3,700 million in 2021 and is projected to grow during the forecast period (2022-2032).
  • According to the estimates, the highest DLBCL market size is of the United States, in 2021 and is anticipated to grow at a CAGR of 10.4%.
  • Among EU4 countries, Germany has the maximum revenue share in 2021 while Spain has the lowest DLBCL market share.
  • The DLBCL market size in Japan was USD 448 million in 2021 which is expected to rise during the forecast period (2022-2032).

The United States: DLBCL Market Outlook

The total DLBCL market size in the United States is expected to increase with a CAGR of 10.4% during the study period (2019–2032).

EU4, the UK: DLBCL Market Outlook

The total DLBCL market size in EU4 and the UK is expected to increase with a CAGR of 10.2% during the study period (2019–2032).

Japan: DLBCL Market Outlook

The total DLBCL market size in Japan is expected to increase with a CAGR of 8.6% during the study period (2019–2032).

Analyst Commentary

  • DLBCL has an active pipeline as many pharmaceutical companies are working towards developing an effective and affordable therapy in first-line, first-R/R transplant-eligible, first-R/R transplant-ineligible, and subsequent R/R setting.
  • Generic chemotherapy is still the treatment backbone of all B-cell NHL subtypes. Although the addition of rituximab improved outcomes in patients with B-cell lymphomas, a significant number of patients are rituximab refractory at the time of relapse.
  • A new standard of care for the first-line treatment of DLBCL, potentially reducing the need for subsequent treatments and limiting the patient burden, is the need of the hour. As POLIVY is not expected to be approved until April 2023, trends in the first-line DLBCL market remain stable, dominated by RITUXAN-based combinations, particularly R-CHOP.
  • YESCARTA appears to have the upper hand in the battle for CAR-T supremacy in the first-R/R transplant eligible setting given it has been in the market before BREYANZI.
  • There are also many earlier-stage approaches to DLBCL treatment, including next-generation CD19xCD3 specifics, allogenic CD19 CAR-T, next-generation CD19 CAR-T, CD47 targeting agents, and other targets. Through time, it is expected that trials of novel combinations with the CD3xCD20 class to be initiated, which could further broaden the array for 2L DLBCL treatment.
  • When bispecific antibodies are compared to CAR-T cells, an advantage of the patient’s immune system can be taken in the case of bispecific antibodies.
  • CAR-T therapies need intricate manufacturing procedures, requiring more than 2 weeks before the finished product is delivered to the patient for infusion. Additionally, patients must travel to the designated large treatment centers to get CAR-T treatment. But, some drugs are readily available as off-the-shelf therapy, which do not require any wait for the people to start the treatment.

DLBCL Drugs Uptake

This section focuses on the rate of uptake of the potential DLBCL drugs expected to get launched in the market during the study period 2019-2032. The analysis covers DLBCL market uptake by drugs; patient uptake by therapies; and sales of each drug. For example- Epcoritamab which is an investigational IgG1-bispecific antibody created using Genmab’s proprietary DuoBody technology. In November 2022, AbbVie announced that the US FDA has accepted for priority review the Biologics License Application for epcoritamab, to treat adult patients with relapsed/refractory LBCL after two or more lines of systemic therapy. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of May 21, 2023. In October 2022, AbbVie announced that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA) for epcoritamab to treat adult patients with R/R DLBCL after two or more lines of systemic therapy. As per our analysis, epcoritamab drug uptake in the US for subsequent R/R DLBCL is expected to be medium with a probability adjusted peak share of 13%, years to peak would be 6 years.

DLBCL Pipeline Development Activities

The DLBCL Market report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The DLBCL Market report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for DLBCL emerging therapies.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in the domain through primary research to fill the data gaps and validate our secondary research. Some of the leaders from UT Southwestern Medical Center in Dallas, Cancer Research UK Barts Centre in London, MD Anderson Cancer Center. Their opinion helps to understand and validate current and emerging therapies treatment patterns or DLBCL market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the DLBCL market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the DLBCL Market Report

  • The report covers the descriptive overview of DLBCL, explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the DLBCL epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for DLBCL are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of DLBCL market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM DLBCL market.

DLBCL Market Report Highlights

  • In the coming years, DLBCL market is set to change due emerging therapies in the pipeline, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence DLBCL R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • As per DelveInsight’s analysis the major types of DLBCL include diffuse large B-cell lymphoma, NOS, germinal center B-cell-like or GCB subtype, non-GCB types, usually activated B-cell-like (ABC subtype), and others.
  • The report also encompasses other major segments, i.e., total incident population of DLBCL, gender-specific population of DLBCL, age-specific population of DLBCL, type-specific population of DLBCL, and stage-specific population of DLBCL.
  • Expected launch of potential therapies such as Epcoritamab (AbbVie and Genmab), Zilovertamab vedotin (Merck), Glofitamab (Roche), Plamotamab (Xencor and Janssen), Zamtocabtagene autoleucel (Miltenyi Biomedicine), and others might change the landscape in treatment of DLBCL.
  • The US FDA-approved drugs which are currently available include RITUXAN/MABTHERA, YESCARTA, KYMRIAH, XPOVIO, POLIVY, and others.

DLBCL Market Report Insights

  • DLBCL Report Insights
  • Diffuse Large B-cell Lymphoma Patient Population
  • Therapeutic Approaches
  • DLBCL Pipeline Analysis
  • DLBCL Market Size and Trends
  • Diffuse Large B-cell Lymphoma Market Opportunities
  • Impact of upcoming Diffuse Large B-cell Lymphoma Therapies

DLBCL Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • DLBCL Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Diffuse Large B-cell Lymphoma Market
  • Diffuse Large B-cell Lymphoma Drugs Uptake

DLBCL Market Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • SWOT
  • Attribute Analysis

Key Questions

Diffuse Large B-cell Lymphoma Market Insights:

  • What was the DLBCL market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the total DLBCL market size as well as market size by therapies across the 7MM during the study period (2019–2032)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest DLBCL market size during the study period (2019–2032)?
  • At what CAGR, the DLBCL market is expected to grow at the 7MM level during the study period (2019–2032)?
  • What would be the DLBCL market outlook across the 7MM during the study period (2019–2032)?
  • What would be the DLBCL market growth till 2032 and what will be the resultant Diffuse Large B-cell Lymphoma market size in the year 2032?
  • How would the market drivers, barriers and future opportunities affect the Diffuse Large B-cell Lymphoma market dynamics and subsequent analysis of the associated trends?

Diffuse Large B-cell Lymphoma Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of DLBCL?
  • What is the historical DLBCL patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
  • What would be the forecasted patient pool of DLBCL at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to DLBCL?
  • Out of the above-mentioned countries, which country would have the highest incident population of DLBCL during the study period (2019–2032)?
  • At what CAGR the population is expected to grow across the 7MM during the study period (2019–2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the treatment of DLBCL? What are the current treatment guidelines for the treatment of DLBCL in the US and Europe?
  • What are the DLBCL marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of DLBCL?
  • How many emerging Diffuse Large B-cell Lymphoma therapies are in the mid-stage and late stage of development for the treatment of DLBCL?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the DLBCL therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for DLBCL and their status?
  • What are the key designations that have been granted for the emerging therapies for DLBCL?
  • What are the 7MM historical and forecasted Diffuse Large B-cell Lymphoma market?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the DLBCL.
  • To understand the future market competition in the DLBCL market and Insightful review of the SWOT analysis of DLBCL.
  • Organize sales and marketing efforts by identifying the best opportunities for DLBCL in the US, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for DLBCL market.
  • To understand the future market competition in the DLBCL market.

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

5. Epidemiology and Market Forecast Methodology

6. DLBCL Market Overview at a Glance in the 7MM

6.1. Market Share (%) Distribution by Line of Therapies in 2019

6.2. Market Share (%) Distribution by Line of Therapies in 2032

6.3. Market Share (%) Distribution by Class in 2019

6.4. Market Share (%) Distribution by Class in 2032

7. Disease Background and Overview

7.1. Introduction

7.2. Understanding Lymphoma

7.2.1. Types of Lymphoma

7.2.2. Types of Non-Hodgkin’s Lymphomas (NHL)

7.3. Signs and symptoms of DLBCL

7.4. Pathophysiology

7.4.1. Molecular Events Involved in DLBCL Pathogenesis

7.4.2. Main oncogenes involved in the pathogenesis of DLBCL

7.4.3. Main tumor suppressor genes related to the pathogenesis and prognosis of DLBCL

7.4.4. Main transcription factors in the pathogenesis and prognosis of DLBCL

7.5. Classification of DLBCL

7.5.1. Based on Morphology

7.5.2. Based on molecular classification

7.5.3. Rare variants

7.5.4. Other DLBCLs

7.6. WHO classification of DLBCL

7.6.1. 2008 WHO classification

7.6.2. WHO classification of mature large B-cell lymphoid neoplasms

7.6.3. 2016 update of WHO classification of DLBCL: subtypes and related entities

7.7. DLBCL Diagnosis and staging

7.8. Staging

7.8.1. Ann Arbor staging

7.8.2. Cotswolds modification of Ann Arbor staging system

7.8.3. Lugano Modification of Ann Harbor

7.8.4. The International Prognostic Index staging system

7.9. Diagnostic guidelines

7.9.1. Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, of DLBCL

7.10. ESMO Clinical Practice Guidelines for diagnosis

7.10.1. Recommended diagnosis strategies in diffuse large B-cell lymphoma

7.11. DLBCL Biomarkers

7.11.1. Clinical prognostic markers in DLBCL

7.11.2. Molecular prognostic markers

8. Treatment and Guidelines

8.1. Current Treatment Insights

8.2. ESMO Guidelines for treatment of DLBCL

8.3. National Comprehensive Cancer Network (NCCN) Treatment Guideline for DLBCL

8.4. Guidelines: Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma

8.5. British Journal of Haematology: Guidelines for the management of DLBCL

8.6. JSMO-JSCO clinical practice guidelines

9. Epidemiology and Patient Population of 7MM

9.1. Key Findings

9.1.1. Assumption and rationale

9.1.2. Total Incident cases of DLBCL in the 7MM

9.2. The United States

9.2.1. Total Incident cases of DLBCL in the US

9.2.2. Gender-specific cases of DLBCL in the US

9.2.3. Age-specific cases of DLBCL in the US

9.2.4. Type-specific Cases of DLBCL in the US

9.2.5. Stage-specific Incident Cases of DLBCL in the US

9.3. EU4 and the UK

9.3.1. Total Incident cases of DLBCL in EU4 and the UK

9.3.2. Gender-specific cases of DLBCL in EU4 and the UK

9.3.3. Age-specific cases of DLBCL in EU4 and the UK

9.3.4. Type-specific Cases of DLBCL in EU4 and the UK

9.3.5. Stage-specific incident cases of DLBCL in EU4 and the UK

9.4. Japan

9.4.1. Total Incident cases of DLBCL in Japan

9.4.2. Gender-specific cases of DLBCL in Japan

9.4.3. Age-specific cases of DLBCL in Japan

9.4.4. Type-specific Cases of DLBCL in Japan

9.4.5. Stage-specific Incident Cases of DLBCL in Japan

10. Patient Journey

11. Key Endpoints in DLBCL

12. Marketed Drugs

12.1. Key Competitors

12.2. RITUXAN/MABTHERA: Biogen/Genentech/Roche

12.2.1. Product description

12.2.2. Regulatory milestones

12.2.3. Other development activities

12.2.4. Safety and efficacy

12.3. YESCARTA (axicabtagene ciloleucel): Kite (Gilead Sciences)

12.3.1. Product description

12.3.2. Regulatory milestones

12.3.3. Other development activities

12.3.4. Clinical development

12.3.5. Safety and efficacy

12.4. KYMRIAH (tisagenlecleucel): Novartis

12.4.1. Product description

12.4.2. Regulatory milestones

12.4.3. Other development activities

12.4.4. Clinical development

12.4.5. Safety and efficacy

12.5. XPOVIO (selinexor): Karyopharm

12.5.1. Product description

12.5.2. Regulatory milestones

12.5.3. Other development activities

12.5.4. Clinical development

12.5.5. Safety and efficacy

12.6. POLIVY (polatuzumab vedotin-piiq): Roche/Chugai Pharmaceuticals

12.6.1. Product description

12.6.2. Regulatory milestones

12.6.3. Other development activities

12.6.4. Clinical development

12.6.5. Safety and efficacy

12.7. KEYTRUDA (pembrolizumab): Merck Sharp & Dohme

12.7.1. Product description

12.7.2. Regulatory milestones

12.7.3. Other development activities

12.7.4. Clinical development

12.7.5. Safety and efficacy

12.8. ZYNLONTA (loncastuximab tesirine): ADC Therapeutics

12.8.1. Product description

12.8.2. Regulatory milestones

12.8.3. Other development activities

12.8.4. Clinical development

12.8.5. Safety and efficacy

12.9. BREYANZI (lisocabtagene maraleucel): Bristol Myers Squibb

12.9.1. Product description

12.9.2. Regulatory milestones

12.9.3. Other development activities

12.9.4. Clinical development

12.9.5. Safety and efficacy

12.10. MONJUVI/MINJUVI (tafasitamab-cxix): MorphoSys/ Incyte

12.10.1. Product description

12.10.2. Regulatory milestones

12.10.3. Other development activities

12.10.4. Clinical development

12.10.5. Safety and efficacy

12.11. TREAKISYM: SymBio Pharmaceuticals

12.11.1. Product description

12.11.2. Regulatory milestones

12.11.3. Other development activities

12.11.4. Safety and efficacy

13. Emerging Drugs

13.1. Key Competitors

13.2. ASH 2022 key abstract summary for DLBCL

13.3. Epcoritamab: AbbVie and Genmab

13.3.1. Product description

13.3.2. Other developmental activities

13.3.3. Clinical development

13.3.4. Safety and efficacy

13.4. Zilovertamab vedotin: Merck

13.4.1. Product description

13.4.2. Other developmental activities

13.4.3. Clinical development

13.4.4. Safety and efficacy

13.5. Glofitamab: Roche

13.5.1. Product description

13.5.2. Other developmental activities

13.5.3. Clinical development

13.5.4. Safety and efficacy

13.6. Plamotamab: Xencor and Janssen

13.6.1. Product description

13.6.2. Other developmental activities

13.6.3. Clinical development

13.6.4. Safety and efficacy

13.7. Enzastaurin (DB102): Denovo Biopharma

13.7.1. Product description

13.7.2. Other developmental activities

13.7.3. Clinical development

13.7.4. Safety and efficacy

13.8. Mivavotinib: Calithera Biosciences

13.8.1. Product description

13.8.2. Other developmental activities

13.8.3. Clinical development

13.8.4. Safety and efficacy

13.9. Maveropepimut-S: IMV

13.9.1. Product description

13.9.2. Other developmental activities

13.9.3. Clinical development

13.9.4. Safety and efficacy

13.10. LUNSUMIO (mosunetuzumab): Roche and Biogen

13.10.1. Product description

13.10.2. Other developmental activities

13.10.3. Clinical development

13.10.4. Safety and efficacy

13.11. Obe-cel: Autolus Therapeutics

13.11.1. Product description

13.11.2. Clinical development

13.11.3. Safety and efficacy

13.12. ALLO-501A: Allogene Therapeutics

13.12.1. Product description

13.12.2. Other developmental activities

13.12.3. Clinical development

13.12.4. Safety and efficacy

13.13. YTB323: Novartis

13.13.1. Product description

13.13.2. Clinical development

13.13.3. Safety and efficacy

13.14. Zamtocabtagene autoleucel (MB-CART2019.1): Miltenyi Biomedicine

13.14.1. Product description

13.14.2. Other developmental activities

13.14.3. Clinical development

13.14.4. Safety and efficacy

13.15. Odronextamab (REGN1979): Regeneron Pharmaceuticals

13.15.1. Product description

13.15.2. Other developmental activities

13.15.3. Clinical development

13.15.4. Safety and efficacy

13.16. Debio 1562: Debiopharm

13.16.1. Product description

13.16.2. Other developmental activities

13.16.3. Clinical development

13.16.4. Safety and efficacy

13.17. ADCETRIS (Brentuximab Vedotin): Seagen/Takeda

13.17.1. Product description

13.17.2. Other developmental activities

13.17.3. Clinical development

13.17.4. Safety and efficacy

13.18. Magrolimab: Gilead Sciences

13.18.1. Product description

13.18.2. Clinical development

13.18.3. Safety and efficacy

13.19. IMFINZI (durvalumab): AstraZeneca

13.19.1. Product profile

13.19.2. Other developmental activities

13.19.3. Clinical development

13.19.4. Safety and Efficacy

13.20. CALQUENCE (acalabrutinb): AstraZeneca

13.20.1. Product description

13.20.2. Other developmental activities

13.20.3. Clinical development

13.20.4. Safety and efficacy

14. DLBCL: 7MM Market Analysis

14.1. Key Findings

14.2. Total Market Size of DLBCL in the 7MM

14.3. Market Outlook

14.4. Attribute Analysis

14.5. Key Market Forecast Assumptions

14.6. United States Market Size

14.6.1. Total Market Size of DLBCL in the United States

14.6.2. Market Size of DLBCL by First-line Therapies in the United States

14.6.3. Market Size of DLBCL by First R/R Transplant Eligible Therapies in the United States

14.6.4. Market Size of DLBCL by First R/R Transplant Ineligible Therapies in the United States

14.6.5. Market Size of DLBCL by R/R Subsequent Therapies in the United States

14.7. EU4 and the UK Market Size

14.7.1. Total Market Size of DLBCL in EU4 and the UK

14.7.2. Market Size of DLBCL by First-line Therapies in EU4 and the UK

14.7.3. Market Size of DLBCL by First R/R Transplant Eligible Therapies in EU4 and the UK

14.7.4. Market Size of DLBCL by First R/R Transplant Ineligible Therapies in EU4 and the UK

14.7.5. Market Size of DLBCL by R/R Subsequent Therapies in EU4 and the UK

14.8. Japan Market Size

14.8.1. Total Market Size of DLBCL in Japan

14.8.2. Market Size of DLBCL by First-line Therapies in Japan

14.8.3. Market Size of DLBCL by First R/R Transplant Eligible Therapies in Japan

14.8.4. Market Size of DLBCL by First R/R Transplant Ineligible Therapies in Japan

14.8.5. Market Size of DLBCL by R/R Subsequent Therapies in Japan

15. Unmet Needs

16. SWOT Analysis

17. KOL Views

18. Market Access and Reimbursement

18.1. CAR-T market access and reimbursement

18.1.1. YESCARTA (axicabtagene ciloleucel): Gilead Life Sciences

18.1.2. KYMRIAH (tisagenlecleucel): Novartis

18.1.3. BREYANZI (lisocabtagene maraleucel): BMS

18.2. XPOVIO (selinexor): Karyopharm Therapeutics

18.3. KEYTRUDA (pembrolizumab): Merck Sharp & Dohme

18.4. POLIVY (polatuzumab vedotin): Roche–Genentech/Chugai Pharmaceuticals

18.5. MONJUVI (tafasitamab): MorphoSys AG/Incyte

18.6. RITUXAN/MABTHERA (rituximab): Biogen/Genentech

18.7. ZYNLONTA (loncastuximab tesirine): ADC Therapeutics

18.8. Scenario of Emerging Drugs Reimbursement Programs

19. Appendix

19.1. Bibliography

19.2. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

List of Tables:

  • Table 1: Summary of DLBCL Market, and Epidemiology (2019–2032)
  • Table 2: Key Events
  • Table 3: Genetic lesions associated with different subtypes of DLBCL.
  • Table 4: 2016 update of the WHO classification of DLBCL: subtypes and related entities
  • Table 5: 2016 WHO classification of mature lymphoid, histiocytic, and dendritic neoplasms
  • Table 6: DLBCL Ann Arbor staging
  • Table 7: Cotswolds modification of the Ann Arbor staging system
  • Table 8: Lugano modification of the Ann Arbor staging system (2014)
  • Table 9: The International Extranodal Lymphoma Study Group (IELSG) staging system for DLBCL of the bone
  • Table 10: NCCN-International Prognostic Index
  • Table 11: Spanish Guidelines
  • Table 12: Recommended treatment strategies in DLBCL
  • Table 13: Spanish Lymphoma Group (GELTAMO) Guidelines
  • Table 14: Summary and recommendations for DLBCL response evaluation and follow-up
  • Table 15: Summary and recommendations for DLBCL response evaluation and follow-up
  • Table 16: Total incident cases of DLBCL in the 7MM (2019–2032)
  • Table 17: Total incident cases of DLBCL in the US (2019–2032)
  • Table 18: Gender-specific cases of DLBCL in the US (2019–2032)
  • Table 19: Age-specific cases of DLBCL in the US (2019–2032)
  • Table 20: Type-specific cases of DLBCL in the US (2019–2032)
  • Table 21: Stage-specific incident cases of DLBCL in the US (2019–2032)
  • Table 22: Total incident cases of DLBCL in EU4 and the UK (2019–2032)
  • Table 23: Gender-specific cases of DLBCL in EU4 and the UK (2019–2032)
  • Table 24: Age-specific cases of DLBCL in EU4 and the UK (2019–2032)
  • Table 25: Type-specific cases of DLBCL in EU4 and the UK (2019–2032)
  • Table 26: Stage-specific Incident Cases of DLBCL in EU4 and the UK (2019–2032)
  • Table 27: Total Incident cases of DLBCL in Japan (2019–2032)
  • Table 28: Gender-specific cases of DLBCL in Japan (2019–2032)
  • Table 29: Age-specific cases of DLBCL in Japan (2019–2032)
  • Table 30: Type-specific Cases of DLBCL in Japan (2019–2032)
  • Table 31: Stage-specific incident Cases of DLBCL in Japan (2019–2032)
  • Table 32: Comparison of Marketed Products
  • Table 33: YESCARTA, Clinical Trial Description, 2022
  • Table 34: KYMRIAH (tisagenlecleucel), Clinical trial description, 2022
  • Table 35: XPOVIO, Clinical Trial Description, 2022
  • Table 36: POLIVY, Clinical Trial Description, 2022
  • Table 37: KEYTRUDA (pembrolizumab), Clinical Trial Description, 2022
  • Table 38: ZYNLONTA, Clinical Trial Description, 2022
  • Table 39: BREYANZI, Clinical Trial Description, 2022
  • Table 40: MONJUVI, Clinical Trial Description, 2022
  • Table 41: Comparison of Emerging Drugs
  • Table 42: Key abstracts summary presented at ASH 2022
  • Table 43: Epcoritamab, Clinical Trial Description, 2022
  • Table 44: Zilovertamab vedotin, Clinical Trial Description, 2022
  • Table 45: Glofitamab, Clinical Trial Description, 2022
  • Table 46: Plamotamab, Clinical Trial Description, 2022
  • Table 47: Enzastaurin, Clinical Trial Description, 2022
  • Table 48: Mivavotinib, Clinical Trial Description, 2022
  • Table 49: Maveropepimut-S, Clinical Trial Description, 2022
  • Table 50: LUNSUMIO, Clinical Trial Description, 2022
  • Table 51: Obe-cel, Clinical Trial Description, 2022
  • Table 52: ALLO-501A, Clinical Trial Description, 2022
  • Table 53: YTB323, Clinical Trial Description, 2022
  • Table 54: Zamtocabtagene autoleucel, Clinical Trial Description, 2022
  • Table 55: Odronextamab, Clinical Trial Description, 2022
  • Table 56: Debio 1562, Clinical Trial Description, 2022
  • Table 57: ADCETRIS (brentuximab vedotin), Clinical Trial Description, 2022
  • Table 58: Magrolimab, Clinical Trial Description, 2022
  • Table 59: IMFINZI, Clinical Trial Description, 2022
  • Table 60: CALQUENCE, Clinical Trial Description, 2022
  • Table 61: Market Size of DLBCL in the 7MM, USD million (2019–2032)
  • Table 62: Key Market Forecast Assumptions for Acalabrutinib + R-CHOP
  • Table 63: Key Market Forecast Assumptions for Enzastaurin + R-CHOP
  • Table 64: Key Market Forecast Assumptions for POLIVY + R-CHP
  • Table 65: Key Market Forecast Assumptions for Epcoritamab
  • Table 66: Key Market Forecast Assumptions for Glofitamab
  • Table 67: Key Market Forecast Assumptions for ZYNLONTA
  • Table 68: Key Market Forecast Assumptions for ADCETRIS + Lenalidomide + Rituximab
  • Table 69: Key Market Forecast Assumptions for LUNSUMIO + Polatuzumab vedotin
  • Table 70: Key Market Forecast Assumptions for TREAKISYM + Rituximab
  • Table 71: Key Market Forecast Assumptions for Plamotamab + Tafasitamab + Lenalidomide
  • Table 72: Key Market Forecast Assumptions for Zilovertamab Vedotin + R-GemOx
  • Table 73: Key Market Forecast Assumptions for Odronextamab
  • Table 74: Key Market Forecast Assumptions for ALLO-501A
  • Table 75: Key Market Forecast Assumptions for Debio 1562 + rituximab
  • Table 76: Key Market Forecast Assumptions for Mivavotinib
  • Table 77: Key Market Forecast Assumptions for Maveropepimut-S + Pembrolizumab ± Cyclophosphamide
  • Table 78: Key Market Forecast Assumptions for Zamtocabtagene Autoleucel (MB-CART2019.1)
  • Table 79: Key Market Forecast Assumptions for YESCARTA
  • Table 80: Key Market Forecast Assumptions for BREYANZI
  • Table 81: Key Market Forecast Assumptions for MONJUVI
  • Table 82: Key Market Forecast Assumptions for XPOVIO ± R-GDP
  • Table 83: Market Size of DLBCL in the United States, USD million (2019–2032)
  • Table 84: Market Size of DLBCL by First-line Therapies in the United States, USD million (2019–2032)
  • Table 85: Market Size of DLBCL by First R/R Transplant Eligible Therapies in the United States, USD million (2019–2032)
  • Table 86: Market Size of DLBCL by First R/R Transplant Ineligible Therapies in United State, USD million (2019–2032)
  • Table 87: Market Size of DLBCL by R/R Subsequent Therapies in the United States, USD million (2019–2032)
  • Table 88: Market Size of DLBCL in EU4 and the UK, USD million (2019–2032)
  • Table 89: Market Size of DLBCL by First-lineTherapies in EU4 and the UK, USD million (2019–2032)
  • Table 90: Market Size of DLBCL by First R/R Transplant Eligible Therapies in the EU4 and the UK, USD million (2019–2032)
  • Table 91: Market Size of DLBCL by First R/R Transplant Ineligible Therapies in EU4 and the UK, USD million (2019–2032)
  • Table 92: Market Size of DLBCL by R/R Subsequent Therapies in EU4 and the UK, USD million (2019–2032)
  • Table 93: Total Market Size of DLBCL in Japan, USD million (2019–2032)
  • Table 94: Market Size of DLBCL by First-line Therapies in Japan, USD million (2019–2032)
  • Table 95: Market Size of DLBCL by First R/R Transplant Eligible Therapies in Japan, USD million (2019–2032)
  • Table 96: Market Size of DLBCL by First R/R Transplant Ineligible Therapies in Japan, USD million (2019–2032)
  • Table 97: Market Size of DLBCL by R/R Subsequent Therapies in Japan, USD million (2019–2032)
  • Table 98: A Summary Overview of List Prices, Reimbursement Schemes, and key Outcomes Associated With the Reimbursement of CAR-T cell Therapies in the EU4 (Germany, France, Italy, and Spain) and the UK
  • Table 99: Key Events During the development of the Guidance
  • Table 100: Costs for the GKV for the drug to be Evaluated per Patient Based on 1-year

List of Figures:

  • Figure 1: Types of Lymphomas
  • Figure 2: Most Common Subtypes of Non-Hodgkin Lymphoma (NHL)
  • Figure 3: Signs and Symptoms of DLBCL
  • Figure 4: Diagram of the differentiation and maturation of normal B lymphocytes and possible molecular alterations that can lead to the pathogenesis of diffuse large B-Cell lymphoma
  • Figure 5: Main genetic lesions that occur in the pathogenesis of diffuse large B-Cell lymphoma (DLBCL) and their respective frequencies.
  • Figure 6: Classification of DLBCL
  • Figure 7: Staging Systems for DLBCL
  • Figure 8: First Line Therapy Algorithm for DLBCL (Spanish Lymphoma Group (GELTAMO) Guidelines)
  • Figure 9: Salvage Therapy Algorithm for DLBCL (Spanish Lymphoma Group (GELTAMO) Guidelines)
  • Figure 10: Total incident cases of DLBCL in the 7MM (2019–2032)
  • Figure 11: Total incident cases of DLBCL in the US (2019–2032)
  • Figure 12: Gender-specific cases of DLBCL in the US (2019–2032)
  • Figure 13: Age-specific cases of DLBCL in the US (2019–2032)
  • Figure 14: Type-specific cases of DLBCL in the US (2019–2032)
  • Figure 15: Stage-specific incident Cases of DLBCL in the US (2019–2032)
  • Figure 16: Total incident cases of DLBCL in EU4 and the UK (2019–2032)
  • Figure 17: Gender-specific cases of DLBCL in EU4 and the UK (2019–2032)
  • Figure 18: Age-specific cases of DLBCL in EU4 and the UK (2019–2032)
  • Figure 19: Type-specific cases of DLBCL in EU4 and the UK (2019–2032)
  • Figure 20: Stage-specific Incident Cases of DLBCL in EU4 and the UK (2019–2032)
  • Figure 21: Total Incident cases of DLBCL in Japan (2019–2032)
  • Figure 22: Gender-specific cases of DLBCL in Japan (2019–2032)
  • Figure 23: Age-specific cases of DLBCL in Japan (2019–2032)
  • Figure 24: Type-specific Cases of DLBCL in Japan (2019–2032)
  • Figure 25: Stage-specific incident Cases of DLBCL in Japan (2019–2032)
  • Figure 26: Market Size of DLBCL in the 7MM, USD million (2019–2032)
  • Figure 27: Market Size of DLBCL in the United States, USD million (2019–2032)
  • Figure 28: Market Size of DLBCL by First-line Therapies in the United States, USD million (2019–2032)
  • Figure 29: Market Size of DLBCL by First R/R Transplant Eligible Therapies in the United States, USD million (2019–2032)
  • Figure 30: Market Size of DLBCL by First R/R Transplant Ineligible Therapies in the United States, USD million (2019–2032)
  • Figure 31: Market Size of DLBCL by R/R Subsequent Therapies in the United States, USD million (2019–2032)
  • Figure 32: Market Size of DLBCL in EU4 and the UK, USD million (2019–2032)
  • Figure 33: Market Size of DLBCL by First-line Therapies in EU4 and the UK, USD million (2019–2032)
  • Figure 34: Market Size of DLBCL by First R/R Transplant Eligible Therapies in the EU4 and the UK, USD million (2019–2032)
  • Figure 35: Market Size of DLBCL by First R/R Transplant Ineligible Therapies in the EU4 and the UK, USD million (2019–2032)
  • Figure 36: Market Size of DLBCL by R/R Subsequent Therapies in EU4 and the UK, USD million (2019–2032)
  • Figure 37: Total Market Size of DLBCL in Japan, USD million (2019–2032)
  • Figure 38: Market Size of DLBCL by First-line Therapies in Japan, USD million (2019–2032)
  • Figure 39: Market Size of DLBCL by First R/R Transplant Eligible Therapies in Japan, USD million (2019–2032)
  • Figure 40: Market Size of DLBCL by First R/R Transplant Ineligible Therapies in Japan , USD million (2019–2032)
  • Figure 41: Market Size of DLBCL by R/R Subsequent Therapies in Japan, USD million (2019–2032)

List of Companies:

  • AbbVie and Genmab
    Merck
    Roche
    Xencor and Janssen
    Denovo Biopharma
    Calithera Biosciences
    IMV
    Biogen
    Autolus Therapeutics
    Allogene Therapeutics
    Novartis
    Miltenyi Biomedicine
    Regeneron Pharmaceuticals
    Debiopharm
    Seagen
    Takeda
    AstraZeneca
    Gilead Sciences
Diffuse Large B-cell Lymphoma

Related Reports

Diffuse Large B-Cell Lymphoma - Pipeline Insight, 2023

Diffuse Large B-Cell Lymphoma - Pipeline Insight, 2023

Diffuse Large B-cell Lymphoma - Epidemiology Forecast - 2032

Diffuse Large B-cell Lymphoma - Epidemiology Forecast - 2032

Tags:

loader

Request Sample

View Pricing